Robert Schooley, MD, Infectious Disease, La Jolla, CA, UC San Diego Medical Center – Hillcrest

RobertTurnerSchooleyMD

Infectious Disease La Jolla, CA

HIV/AIDS Medicine, International Health, Travel & Tropical

Professor, Medicine, UCSD School of Medicine

Dr. Schooley is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Schooley's full profile

Already have an account?

  • Office

    University of California San Diego
    Student Services Center, Mail Stop 0003
    La Jolla, CA 92093
    Phone(858) 246-2693
  • Is this information wrong?

Education & Training

  • Massachusetts General Hospital
    Massachusetts General HospitalFellowship, Infectious Disease, 1979 - 1981
  • National Institute of Allergy and Infectious DiseasesFellowship, Infectious Disease, 1976 - 1979
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1974 - 1976
  • The Johns Hopkins HospitalInternship, Medicine, 1974 - 1975
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1974
  • Washington and Lee UniversityBS, 1970

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2005 - 2022
  • CO State Medical License
    CO State Medical License 1990 - 2021
  • MD State Medical License
    MD State Medical License 1974 - 1983
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • Who's Who in America 1995-2018
  • Gold Doc Arnold P. Gold Foundation, 2009
  • Chief Residents’ Clinical Teaching University of California, San Diego, 2007
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Successful Treatment of Antibiotic Resistant Poly-Microbial Bone Infection with Bacteriophages and Antibiotics Combination  
    Robert Schooley, MD, Clinical Infectious Diseases
  • Oa the Evolution of Mentorship Capacity Development in Low- and Middle-Income Countries: Case Studies from Peru, Kenya, India, and Mozambique  
    Robert Schooley, MD, The American Journal of Tropical Medicine and Hygiene
  • A Phase I Study of Combination Therapy with L-697, 661 and Zidovudine.  
    Schooley RT, Campbell TB, Kuritzkes DR, Blaschke T, Stein DS, Rosandich ME, Phair J, Pottage JC, Messari FA, Collier A, Kahn J and the ACTG 184 Protocol Team, J AIDS & Human Retrovirology. 1996; 12:363-70
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Long-term propagation of New World primate T-lymphocytes in vitro.
    Falk Jr. LA, Silva D, Byington R and Schooley RT, Fifteenth International Leukocyte Culture Conference. Intercell Communicat in Leucocyte Function

Other

  • Therapeutic decision making in 1997. 
    Cotton D, Bartlett J, Schooley R, Gulick R
  • Check, but not checkmate. 
    Schooley RT, Antiviral Therapy. 1997; 2:68-9
  • Antiretroviral chemotherapy. 
    Saag MS and Schooley RT, Curr Clin Top Infect Dis. 1998; 18:154- 79
  • Join now to see all

Press Mentions

  • Growing Consensus That Schools Do Not Contribute to COVID-19 Spread Is Complicated by Worsening Surge
    Growing Consensus That Schools Do Not Contribute to COVID-19 Spread Is Complicated by Worsening SurgeJanuary 11, 2021 10:37
  • Morning Report: If Power Went Public
    Morning Report: If Power Went PublicDecember 17, 2020 11:33
  • 'We're Backed into a Corner': Two Experts on the Best Path to Reopening
    'We're Backed into a Corner': Two Experts on the Best Path to ReopeningDecember 16, 2020 17:17
  • Join now to see all

Grant Support

  • Orally Active Nucleoside Phosphonates For Hepatitis C VirusNational Institute Of Allergy And Infectious Diseases2009–2012
  • Multiplex Nucleic Acid Detection Devices For The Diagnosis Of Respiratory VirusesNational Institute Of Allergy And Infectious Diseases2007–2011
  • International ProgramNational Institute Of Allergy And Infectious Diseases2006–2011
  • Research In Infectious DiseasesNational Institute Of Allergy And Infectious Diseases2005–2011
  • Biochip Diagnostic Tool For Bt Induced DiseasesNational Institute Of Allergy And Infectious Diseases2005–2007
  • The Role Of Sex And HCV Co-Infection In HIV TherapyNational Institute Of Allergy And Infectious Diseases2004
  • ACTG A5116:2 Regimen Trial For HIV SubjectsNational Center For Research Resources2004
  • U Of Colorado Center For AIDS ResearchNational Institute Of Allergy And Infectious Diseases2003–2004
  • Immunopathogenesis Of Acute HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases2003
  • Colorado Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases2000–2003
  • University Of Colorado HIV Research Training ProgramNational Institute Of Allergy And Infectious Diseases1992–2003
  • Subcutaneous IL-2 In Combination With HaartNational Center For Research Resources2000–2002
  • Dynamics Of HCV Infection During Antiretroviral TherapyNational Center For Research Resources2000–2002
  • Chemotherapy/Immunotherapy For HIV InfectionNational Center For Research Resources2000–2002
  • Soft Gelatin Capsule Of Saquinavir In Comb WI Ritonavir Or NelfinavirNational Center For Research Resources1999–2002
  • Phase III Trial:Efavirenz/ Nelfinavir In Combination WI Lamivudine/ZidovudineNational Center For Research Resources1999–2002
  • Phase II Stdy Indinavir+Nevirapine+Stavudine In Subj Prev Trtd W/ 141w94/Vx-478National Center For Research Resources1999–2002
  • Phase II Prolong Virologic Success &Optn For Failure In HIV Sub On IndinavirNational Center For Research Resources1999–2002
  • Actg384 Protease Inhibitor &/Or NON Nucleoside Reverse Trans InhibitorNational Center For Research Resources1999–2002
  • ACTG 398, Phase II Trial Of Amprenavir As PART Of Dual Protease InhibNational Center For Research Resources1999–2002
  • ACTG 362 Trials Of Azithromycin Prophylaxis To Prevent MAC DiseaseNational Center For Research Resources1999–2002
  • ACTG 323 Fluconazole As Therapy For Oropharyngeal CandidiasisNational Center For Research Resources1999–2002
  • A5025 Phase II Random Study Of Hydroxyurea In Subj On Potent AntiretroviralsNational Center For Research Resources1999–2002
  • Actg368 Indinavir Sulfate, Dmp266 &1592u89 In HIV Infected SubjectsNational Center For Research Resources1998–2002
  • 3 Maintenence Regimens For HIV Subjects REC Zidovudine, Lamivudine, IndinavirNational Center For Research Resources1998–2002
  • Immunopathogenesis Of Acute HIV-1 InfectionNational Institute Of Allergy And Infectious Diseases1997–2002
  • Adult ACTG Central GroupNational Institute Of Allergy And Infectious Diseases1999–2001
  • Actg347 Phase II Study Of 141w94/Vx478 Monotherapy VS 141w94/Vx + ZidovudineNational Center For Research Resources1998–2000
  • Virologic Responses To New Nucleoside Regimens After ZDV Or DDI MonotherapyNational Center For Research Resources1997–2000
  • Influence Of Risk Status For Disease Progression On The Response To InterventionNational Center For Research Resources1997–2000
  • ACTG 320 Phase III Indinavir SulfateNational Center For Research Resources1997–2000
  • ACTG 315 Ritonavir, Zidovudine And Lamivudine In Advanced HIV 1 DiseaseNational Center For Research Resources1997–2000
  • ACTG 285 Stem Cell Mobilization And Harvesting With FilgrastimNational Center For Research Resources1997–2000
  • Safety, Tolerability And Pharmacokinetics Of Thalidomide In HIV1 PatientsNational Center For Research Resources1998–1999
  • Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Outreach AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Neurology AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1997–1999
  • Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1997–1999
  • Zdv/Ddi Regimens On Measures Of Viral Burden In Early HIV-1 InfectionNational Center For Research Resources1997–1999
  • Phase II/III Double-Blind Study Of Amytryptilene/Mexiletine For HIV NeuropathyNational Center For Research Resources1997–1999
  • Interleukin 2 PLUS Antiretroviral Therapy VS Antiretroviral TherapyNational Center For Research Resources1997–1999
  • D4T VS DDI VS ZDV PLUS D4T VS ZDV PLUS DDI In HIV Infected PatientsNational Center For Research Resources1997–1999
  • ACTG 333--Hard Capsule And Soft Capsule Saquinavir VS IndinavirNational Center For Research Resources1997–1999
  • Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Outreach AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Neurology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1996–1999
  • Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
  • AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1996–1999
  • Dapsone And Atovaquone Study For PCP In HIV Infected PatientsNational Center For Research Resources1996–1999
  • Adult ACTG Central GroupNational Institute Of Allergy And Infectious Diseases1996–1998
  • Trial To Evaluate Activity Of 141W94 In Patients With HIV InfectionNational Center For Research Resources1997
  • Random Dbl-Bld, Combination Of Nucleoside And Triple Convergent Therapy For HIVNational Center For Research Resources1997
  • Phase I/II Open-Label Trial Of Delavirdine Mesylate (Dlv, U-90152s)National Center For Research Resources1997
  • Evaluation Of STD Therapy VS STD Therapy W/Msl 109 In AIDS Patients W/CmvNational Center For Research Resources1997
  • Delavirdine And ZDV Or Didanosine VS ZDV And DDI Combination TherapyNational Center For Research Resources1997
  • 1592U89 Alone And With Retrovir For HIV Infection (Glaxo/Wellcome (131-002)National Center For Research Resources1997
  • Phase II/III Clarithromycin Regimens For MAC In HIV Positive PatientsNational Center For Research Resources1996–1997
  • HIV-1 Derived Immunogens In Infected Individuals W/500 CD4 Cells/Mm3National Center For Research Resources1996–1997
  • ACTG 175--Monotherapy VS Combination Therapy In HIV PTS, CD4 200-500National Center For Research Resources1996–1997
  • Conference On Immunopathogenesis Of HIV InfectionNational Institute Of Allergy And Infectious Diseases1996
  • Short Term Clinical And Virologic Significance Of ZDV ResistanceNational Center For Research Resources1996
  • ACTG 303--Influence Of Risk Status For Disease ProgressionNational Center For Research Resources1996
  • ACTG 290-D4t VS DDI VS ZDV PLUS D4T VS ZDV PLUS DDI In HIV Positive PatientsNational Center For Research Resources1996
  • ACTG 276--Various Zdv/Ddi Regimens On Measures Of Viral BurdenNational Center For Research Resources1996
  • ACTG 261--Delavirdine And ZDV VS ZDV And DDI Combination TherapyNational Center For Research Resources1996
  • ACTG 260--Phase I/II Trial Of Delavirdine MesylateNational Center For Research Resources1996
  • ACTG 259--Phase II SC 49483 With ZDV Versus ZDVNational Center For Research Resources1996
  • ACTG 248--Interleukin 2 PLUS Antiretroviral Therapy VS Antiretroviral TherapyNational Center For Research Resources1996
  • ACTG 241--Ddi PLUS Nevirapine Versus ZDV PLUS DDINational Center For Research Resources1996
  • ACTG 209--Phase I/II Trial Vaccine Therapy In HIV1 Infected IndividualsNational Center For Research Resources1996
  • ACTG 206--Alpha Interferon With DDI For Patients With Kaposis SarcomaNational Center For Research Resources1996
  • ACTG 204a--Valacyclovir Hydrocholoride Study In HIV Positive PatientsNational Center For Research Resources1996
  • ACTG 193a--Nucleoside And Triple Convergent Therapy For HIVNational Center For Research Resources1996
  • 1592U89 Alone And With Retrovir For HIV InfectionNational Center For Research Resources1996
  • Ribozymes As Molecular Therapies For AIDSNational Institute Of Allergy And Infectious Diseases1994–1996
  • AIDS Clinical TrialsNational Institute Of Allergy And Infectious Diseases1994–1995
  • Cell Mediated Immune Response To Human RetrovirusesNational Cancer Institute1990–1994
  • Colorado AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–1993
  • AIDS &Related Research 1 Study SectionCenter For Scientific Review1990
  • Cellular Immune Response To HIVNational Cancer Institute1987–1989
  • Human T-Cell Leukemia Virus--Virus-Host InteractionsNational Cancer Institute1985–1986

Committees

  • Member, Scientific Advisory Board, PEPFAR, US Department of State 2011 - Present
  • Chair, NIH Drug Discovery and Resistance (DDR) Study Section 2011 - 2013

Hospital Affiliations